生产企业：Alltrna
AP003 is a chemically modified, engineered tRNA therapeutic designed to restore full-length protein production by inserting the correct amino acid at an Arg-TGA (arginine-to-stop) nonsense mutation. It is formulated as an engineered tRNA oligonucleotide in a clinically validated, liver-directed lipid nanoparticle (LNP).
Nonsense-mutation-driven genetic diseases: AP003 targets the arginine-to-TGA (Arg-TGA) nonsense mutation, one of the most common premature termination codon (PTC) variants found in human genetic diseases. Alltrna is developing AP003 through a basket approach as a novel treatment for inborn errors of metabolism affecting the liver.
共 1 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
